drugset
drugset / Trial / NCT02658825

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

NCT02658825 ↗

Phase 1 Completed 66 enrolled Janssen Research & Development, LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect of JNJ-63623872 on the QT/QTc interval at supratherapeutic exposure in healthy participants (Panel 2).

Timeline

Start
2016-01
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral
Subject Pimodivir Small molecule 2400 mg Oral
Subject Pimodivir Small molecule 3000 mg Oral

Indications

No indication recorded.